Skip to main content
Evidence Snapshot

Dipeptidyl peptidase 4

CHEMBL284 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T13:14:56Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL284
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Dipeptidyl peptidase 4 as ChEMBL target CHEMBL284, mapped to UniProt P27487. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Dipeptidyl peptidase 4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL284
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P27487
Dipeptidyl peptidase 4
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Dipeptidyl peptidase 4 matters

As of 2026-09-13

Dipeptidyl peptidase 4 is reviewed as Dipeptidyl peptidase 4 (UniProt P27487); Dipeptidyl peptidase 4 shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block.; 18 linked drugs keep this evidence frame grounded.; the current evidence base includes 30 approved drugs, 5680 compounds, and 615 assays, with lead potency reaching pChEMBL 10.5.

Disease context
type 2 diabetes mellitus

Dipeptidyl peptidase 4 shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block. 18 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ALOGLIPTIN BENZOATE, ANAGLIPTIN, BISEGLIPTIN.

Start review with type 2 diabetes mellitus because it currently carries approved-linked support. Linked drugs include ALOGLIPTIN BENZOATE, ANAGLIPTIN, BISEGLIPTIN, CARMEGLIPTIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 18 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 30 approved drugs, 5680 compounds, and 615 assays for this target. The dominant activity type is IC50. CHEMBL63860 is the current potency anchor at pChEMBL 10.5.

Use CHEMBL63860 as the tractability anchor when discussing potency (pChEMBL 10.5).

Activity source · ChEMBL 36 via Core Engine
30 approved pChEMBL 10.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Dipeptidyl peptidase 4 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P27487, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why type 2 diabetes mellitus is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

5680
Total Compounds
615
Total Assays
30
Approved Drugs
IC50: 5748.0, KI: 704.0, EC50: 4.0, KD: 26.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL63860
 10.5 Ki —
No preferred name
CHEMBL4113723
 10.3 IC50 —
No preferred name
CHEMBL5914058
 10.1 IC50 —
No preferred name
CHEMBL98869
 10.1 Ki —
No preferred name
CHEMBL5269668
 10.1 IC50 —

Approved Drugs

Structure Compound First Approval
GOSOGLIPTIN
CHEMBL515387
 2016
TRELAGLIPTIN
CHEMBL1650443
 2015
EVOGLIPTIN
CHEMBL1779710
 2015
TRELAGLIPTIN SUCCINATE
CHEMBL2105754
 2015
OMARIGLIPTIN
CHEMBL2105762
 2015
ALOGLIPTIN
CHEMBL376359
 2013
ANAGLIPTIN
CHEMBL1929396
 2012
TENELIGLIPTIN
CHEMBL2147777
 2012
LINAGLIPTIN
CHEMBL237500
 2011
SAXAGLIPTIN ANHYDROUS
CHEMBL385517
 2009
VILDAGLIPTIN
CHEMBL142703
 2007
SITAGLIPTIN PHOSPHATE
CHEMBL1201174
 2006
SITAGLIPTIN
CHEMBL1422
 2006
VIDARABINE
CHEMBL1090
 1976
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T13:14:56Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL284